Adenoviral Mediated Gene Therapy for Experimental Glioma

Award Information
Agency:
Department of Health and Human Services
Amount:
$632,576.00
Program:
SBIR
Contract:
1 R43 CA67357-01,
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1997
Phase:
Phase II
Agency Tracking Number:
29220
Solicitation Topic Code:
N/A
Small Business Information
Tsrl, Inc.
540 Avis Drive, Suite A, Ann Arbor, MI, 48108
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 John Hilfinger
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
Gliomas are the most common primary intracranial brain tumors and are thought to arise as a neoplastransformation of glial cells in the central nervous system. The prognosis for the disease is poor.surgical resection of the tumor followed by radiation or chemotherapy. This application describes analternative treatment strategies. The effectiveness of an adenovirus vector to deliver the herpes sikinase (tk) gene to inhibit selectively tumor cell growth upon receipt of ganciclovir (GCV) will beadenovirus vector will be specifically introduced into the tumor area by stereotactic injection; GCVsystemically. The plan is to optimize growth inhibition by determining the effectiveness of redosingdeveloping long term release of infectious virions into the surrounding environment.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government